- Info
- Significant Ownership
- Insider Ownership
Significant Ownership of Laurence W. Lytton
- Signature - Title
- /s/ Laurence W Lytton - Reporting Person
- Location
- NY, NY
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by Laurence W. Lytton.
Follow Filing Activity
Follow Laurence W. Lytton and return when a new Schedule 13D/G filing appears.
This tracks SEC filing changes for this page using existing product update flows.
Continue schedule research
Related filing hubs for this reporting manager, useful for reinforcing crawl paths across the schedule cluster.
Significant Ownership of Laurence W. Lytton
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| AYTU | AYTU BIOPHARMA, INC | Common Stock | 10% | $2,828,367 | -$40,051 | 1,071,351 | -1.4% | LYTTON LAURENCE W | 31 Dec 2025 |
| LIQT | LIQTECH INTERNATIONAL INC | Common Stock | 10% | $2,783,876 | 1,058,508 | Lytton-Kambara Foundation | 30 Sep 2025 | ||
| INAB | IN8BIO, INC. | Common Stock | 10% | $1,928,701 | 984,031 | LYTTON LAURENCE W | 22 Dec 2025 | ||
| GUER | GUERRILLA RF, INC. | Common Stock | 10% | $1,109,943 | 1,088,179 | Lytton, Laurence W. | 28 Mar 2024 | ||
| SNAX | STRYVE FOODS, INC. | Class A Common Stock | 10% | $265,402 | 414,755 | LYTTON LAURENCE W | 31 Dec 2025 | ||
| SONM | DNA X, Inc. | Common Stock | 10% | $103,803 | +$47,844 | 148,290 | +85% | LYTTON LAURENCE W | 31 Dec 2025 |
| IPWR | Ideal Power Inc. | Common Stock | 9.9% | $4,114,160 | 1,210,047 | LYTTON LAURENCE W | 24 Feb 2026 | ||
| APRE | Aprea Therapeutics, Inc. | Common Stock | 9.9% | $913,662 | 681,837 | LYTTON LAURENCE W | 13 Nov 2025 | ||
| CLRB | Cellectar Biosciences, Inc. | Common Stock | 8.8% | $1,147,086 | 3,955,470 | LYTTON LAURENCE W | 31 Dec 2024 | ||
| CGEH | Capstone Green Energy Holdings, Inc. | Common Stock | 7.7% | $8,941,339 | 1,771,404 | LYTTON LAURENCE W | 25 Nov 2025 | ||
| TELA | TELA Bio, Inc. | Common Stock | 7.2% | $4,269,304 | -$832,740 | 2,865,305 | -16% | Lytton, Laurence W. | 30 Sep 2025 |
| MDXH | MDxHealth SA | Ordinary Shares | 6.4% | $14,709,280 | -$3,655,360 | 3,163,286 | -20% | LYTTON LAURENCE W | 30 Sep 2025 |
| ELWT | Elauwit Connection, Inc. | Common Stock | 5.9% | $3,005,860 | 390,879 | LYTTON LAURENCE W | 15 Dec 2025 | ||
| TLPH | TALPHERA, INC. | Common Stock | 5.9% | $2,812,640 | -$932,815 | 2,730,718 | -25% | LYTTON LAURENCE W | 31 Dec 2025 |
| XTNT | Xtant Medical Holdings, Inc. | Common Stock | 5.5% | $5,545,441 | -$1,268,237 | 7,702,002 | -19% | LYTTON LAURENCE W | 31 Dec 2025 |
| CREX | CREATIVE REALITIES, INC. | Common Stock | 5.1% | $1,223,591 | +$213,230 | 534,436 | +21% | LYTTON LAURENCE W | 28 Oct 2025 |
| CDXS | Codexis, Inc. | Common Stock | 5% | $5,347,841 | 4,532,069 | LYTTON LAURENCE W | 06 Mar 2026 | ||
| DUOT | DUOS TECHNOLOGIES GROUP, INC. | Common Stock | 5% | $2,732,813 | 427,002 | LYTTON LAURENCE W | 31 Jan 2024 | ||
| SMTK | SmartKem, Inc. | Common Stock | 4.9% | $525,622 | -$261,044 | 222,721 | -33% | Lytton, Laurence W. | 31 Mar 2025 |
| ELVA | Electrovaya Inc. | Common Shares | 4.7% | $7,272,871 | -$2,085,002 | 1,898,922 | -22% | Lytton, Laurence W. | 30 Jun 2025 |
| EVOK | Evoke Pharma Inc | Common Stock, par value $0.0001 | 3.9% | $158,087 | 61,274 | Lytton, Laurence W. | 31 Mar 2025 | ||
| BFRI | Biofrontera Inc. | Common Stock, par value $0.001 | 3.5% | $254,561 | 306,700 | LYTTON LAURENCE W | 31 Mar 2025 | ||
| NMTC | NEUROONE MEDICAL TECHNOLOGIES Corp | Common Stock, par value $0.001 | 2.6% | $764,220 | 1,295,288 | LYTTON LAURENCE W | 31 Mar 2025 | ||
| CLRB | Cellectar Biosciences, Inc. | Common Stock | 1.6% | $250,788 | 51,391 | LYTTON LAURENCE W | 30 Jun 2025 | ||
| EMKR | EMCORE CORP | Common Stock | 1.4% | $394,948 | 126,948 | LYTTON LAURENCE W | 31 Dec 2024 | ||
| XGN | EXAGEN INC. | Common Stock, par value $0.001 per share | 1% | $1,481,017 | 216,840 | LYTTON LAURENCE W | 30 Jun 2025 | ||
| SCPH | scPharmaceuticals Inc. | Common Stock | 0% | $0 | 0 | LYTTON LAURENCE W | 30 Sep 2025 |
Schedules 13D/G Reported by Laurence W. Lytton:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.